

Potential cholesterol lowering drug has breast cancer fighting capabilities

June 17 2014

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

"Cholesterol is a molecule found in all <u>animal cells</u> and serves as a structural component of cell membranes," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at MU. "Because <u>tumor cells</u> grow rapidly they need to synthesize more <u>cholesterol</u>. Scientists working to cure breast cancer often seek out alternative targets that might slow or stop the progression of the disease, including the elimination of the <u>cancerous cells</u>. In our study, we targeted the production of cholesterol in cancer cells leading to death of breast cancer cells."

Previous studies suggest that 70 percent of breast cancers found in women are hormone dependent and can be treated with anti-hormone medicines such as tamoxifen. Although tumor cells may initially respond to therapies, most eventually develop resistance which causes breast cancer cells to grow and spread. Cholesterol also can contribute to the development of anti-hormone resistance because cholesterol is converted into hormones in tumor cells. Therefore, these cholesterol-forming pathways are attractive therapeutic targets for the treatment of breast cancer.

Using compounds initially developed by Roche Pharmaceuticals for the



treatment of high cholesterol, which reduces cholesterol in a different manner than the widely used statins, Hyder and his team administered the molecule to human <u>breast cancer cells</u>. They found that the compound was effective in reducing human breast cancer cell growth and often caused cancer cell death. Most interestingly they found that the cholesterol lowering drug they tested destroyed an estrogen receptor, a protein which encourages the tumor cells to grow.

Equipped with this information, Hyder and the team tested the results in mice with breast cancer. Following injection of the compound, Hyder found that the molecule was effective at killing <u>breast cancer</u> cells by reducing the presence of estrogen receptors in tumor cells, Hyder said.

"The compound exhibited anti-tumor properties in both human samples, which were outside the body, and in samples that were administered by injection into the mice," Hyder said. "In both cases, the proteins that cause tumors to grow were eliminated, leading to more aggressive cell death."

Hyder believes that further clinical testing can lead to a drug that has the dual purpose of fighting <u>high cholesterol</u> and cancer.

More information: "Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071," *Breast Cancer Research and Treatment*, 2014.

Provided by University of Missouri-Columbia

Citation: Potential cholesterol lowering drug has breast cancer fighting capabilities (2014, June 17) retrieved 28 April 2024 from <u>https://medicalxpress.com/news/2014-06-potential-cholesterol-</u>



lowering-drug-breast.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.